Two of our researchers from Chemical R&D Division presented at the ACS National Meeting held in San Diego, USA, August 25-29, 2019.
Our technologies and experiences in API process research and development, such as these presentations at the conference, is one of SPERA PHARMA’s strengths.
We contribute to the creation of pharmaceutical products for our customers by making full use of the synthesis technologies we have cultivated continuously.
Conference: ACS National Meeting, August 25-29, 2019, San Diego, CA
Venue: Exhibit Hall B, San Diego Convention Center
Title1: Practical Preparation of a 1,3,5-Trisubstituted Pyridazin-4(1H)-one Using Selective C1 Unit Insertion and Cyclization
Presenter: Akihiro Suzuki（Principal Researcher, Chemical R&D Division）
In this presentation, we report the development of a method to efficiently synthesize a PDE10A inhibitor based on the trisubstituted pyridazine-4(1H)-on ring by regioselective cyclization as an active pharmaceutical ingredient process research (Takeda Pharmaceutical Sciences), and furthermore, the production of tens of kilograms of active pharmaceutical ingredients was achieved.
Title2: New Practical Method for Direct Asymmetric Reductive Amination of p-Trifluoromethoxy Acetophenone
Presenter: Masatoshi Yamada（Principal Researcher, Chemical R&D Division）
In this presentation, we report on Direct Asymmetric Reductive Amination (DARA), which we have been working on since the days of Takeda Pharmaceutical Sciences. In particular, we have successfully converted simple acetophenone-type ketones into optically active primary amines that are useful as building blocks for pharmaceuticals.